WHO includes Cadila Pharma Polycap combination in Essential Medicine List
The Polypill formulation (Polycap) is a combination of medications to modify the risk factors like hypercholesterolemia and high blood pressure in patients with atherosclerotic cardiovascular diseases.
Advertisement
Ahmedabad: Cadila Pharmaceuticals has announced the inclusion of “Polypills” for the primary and secondary prevention of cardiovascular diseases in the Essential Medicine List 2023 by the World Health Organization (WHO).
The Cadila polypill formulation (polycap) which was approved in 2009 by DGCI for secondary prevention of coronary heart disease/stroke in patients with multiple risk factors, is included in the Essential Medicine List.
Read also: Prices of 651 essential medicines down by 7 percent
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.